Filing Flows › Comparisons › OVID vs SPRB
Ovid Therapeutics vs Spruce Biosciences: OVID and SPRB compared
Ovid Therapeutics is the larger company: $733K of revenue in its latest quarter (Q2 2026) against $697K for Spruce Biosciences (Q4 2024). Spruce Biosciences is growing faster (-76% against -88% a year earlier).
Where the money goes: OVID and SPRB
Ovid Therapeutics (OVID) · Q2 2026
Ovid Therapeutics, Q2 2026: revenue $733K (-88% year over year), net loss $15.0M, operating cash flow −$17.6M. The chart follows the revenue to costs, profit and cash.
Spruce Biosciences (SPRB) · Q4 2024
Spruce Biosciences, Q4 2024: revenue $697K (-76% year over year), net loss $23.6M, operating cash flow −$20.7M. The chart follows the revenue to costs, profit and cash.
| Ovid Therapeutics (OVID) | Spruce Biosciences (SPRB) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q4 2024 |
| Revenue | $733K | $697K |
| Revenue growth, Y/Y | -88% | -76% |
| Operating margin | n/m | n/m |
| Net earnings | −$15.0M | −$23.6M |
| Operating cash flow | −$17.6M | −$20.7M |
Questions
Which is bigger, Ovid Therapeutics or Spruce Biosciences?
Ovid Therapeutics is the larger company: $733K of revenue in its latest quarter (Q2 2026) against $697K for Spruce Biosciences (Q4 2024).
Is Ovid Therapeutics or Spruce Biosciences growing faster?
Spruce Biosciences is growing faster (-76% against -88% a year earlier).
More: Ovid Therapeutics earnings · how Ovid Therapeutics makes money · Spruce Biosciences earnings · how Spruce Biosciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-K filed Apr 15, 2025). Fiscal quarters can end on different dates. Not investment advice.